LAB RESEARCH RETAINS AGENTS TO RAISE $10 MILLION VIA MARKETED OFFERING
LAVAL, QC, Oct. 14 /CNW Telbec/ - LAB Research Inc. ("LAB Research" or the "Company") (TSX: LRI), a Canadian-based global non-clinical contract research organization, today announced it has retained agents in connection with the marketing of a proposed $10 million public offering pursuant to its $25 million base shelf prospectus filed on August 30, 2010 (the "Offering"). The Offering will be conducted by a syndicate of agents led by Versant Partners Inc. and will include Dundee Capital Markets (the "Agents"). The terms of the Offering, including the type of securities issued and their price, will be determined in due course by the Company and the Agents.
The Company intends to use the gross proceeds from the Offering for working capital purposes and to strengthen its commercial platform. The Offering will be marketed by way of a final short form base shelf prospectus already filed with appropriate Canadian regulatory authorities. The Company expects the Offering to close before the end of November 2010 subject to entering into a formal agency agreement with the Agents and the satisfaction of all necessary regulatory approvals, including the filing of a prospectus supplement with the securities regulatory authorities.
The Company will also grant the Agents an option (the "Agents' Compensation Option") to purchase additional securities in an amount up to 7% of the number of securities sold pursuant to the Offering, exercisable in whole or in part at any time up to twelve months after the Closing.
The Company is seeking to raise capital as part of the strategic review process announced on October 4th, 2010 (the "Strategic Process"). The Strategic Process called for a review of all strategic alternatives available to the Company including a financing, a recapitalization, a strategic partnering, a merger or the sale of all or part of the assets of the Company. Consequently, the Offering represents one of the many alternatives available to LAB Research to strengthen its commercial platform and maximize shareholder value. There is no assurance whether the Company will successfully raise any amount pursuant to this proposed Offering.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws and may not be offered or sold within the United States or to United States persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. This news release is not for distribution to United States newswire services or for dissemination in the United States.
About LAB Research Inc.:
LAB Research is a Canadian global non-clinical contract research organization that provides contract research services to the pharmaceutical, biotechnology, agro-chemical, petro-chemical and industrial markets. LAB Research supports the development of its customers' products from three state-of-the-art facilities located in Canada, Denmark and Hungary.
LAB Research's common shares trade on the TSX under the symbol "LRI", with 52.7 million common shares outstanding.
This news release contains certain forward-looking information that reflect the current views and/or expectations of LAB Research with respect to its performance, business and future events. Such information is subject to a number of risks, uncertainties and assumptions, which are contained in LAB Research's annual information form. Actual results and events may vary significantly. LAB Research specifically disclaims any obligation to update this forward-looking information, unless obligated to do so by applicable securities laws.
%SEDAR: 00023798EFFor further information:
Visit LAB Research's website at www.labresearch.com, or contact:
Chief Executive Officer
Tel: (450) 973-2240 (ext. 1206)
Partner, Jasmin-Dumais Financial Communications
Tel :(514) 862-1251